Posted on June 7th, 2010 by
CHICAGO — Results from the PICASSO trial showed that the combination of palifosfamide and doxorubicin extended PFS by more than three months in patients with soft tissue sarcomas compared with doxorubicin alone. Palifosfamide references a novel DNA crosslinking composition that comprises the functional active metabolite of ifosfamide, but lacks the hemorrhagic cystitis and central nervous system toxicity, according to study background information. Link
Tags: In the News
You must be logged-in to the site to post a comment.